Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $300
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Amgen (NASDAQ:AMGN) and raises the price target from $290 to $300.
October 20, 2023 | 7:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen's price target has been raised from $290 to $300 by Oppenheimer, maintaining an Outperform rating.
The raised price target indicates that the analyst believes the stock has potential to perform well in the future. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100